SCHEMBL30248596

SCHEMBL30248596

O=C(NCc1ccc2c(c1)SCC(=O)N2Cc1ccccc1)Nc1ccc2cc[nH]c2c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.47
MAPT P10636 6/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.42
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
TSHR P16473 1/20 0.40
TP53 P04637 2/20 0.40
TRPA1 O75762 1/20 0.40
ALDH1A1 P00352 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25028537 1.00 ROCK2 (0.47) ROCK2MAPTPOLBGAAMAPK1
SCHEMBL25028539 0.93 MAPT (0.49) ROCK2MAPTPOLBGAAMAPK1
SCHEMBL30248606 0.93 MAPT (0.49) ROCK2MAPTPOLBGAAMAPK1
SCHEMBL23768801 0.91 MAPT (0.45) ROCK2MAPTPOLBKMT2AMEN1
SCHEMBL23768795 0.86 MAPT (0.49) MAPTPOLBMAPK1KMT2AMEN1
SCHEMBL29978870 0.86 MAPT (0.49) MAPTPOLBMAPK1KMT2AMEN1
SCHEMBL31411793 0.85 MAPT (0.51) MAPTPOLBSMN1; SMN2LMNATP53
SCHEMBL30895152 0.84 MAPT (0.46) ROCK2MAPTSMN1; SMN2TP53ALDH1A1
SCHEMBL25028530 0.84 MAPT (0.46) ROCK2MAPTSMN1; SMN2TP53ALDH1A1
SCHEMBL25028532 0.83 ITGB3 (0.48) ROCK2CA12CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384268-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS Curadev Pharma Pvt. Ltd. (IN) 2024-06-19 EP claimed
CN-118019738-A Small molecule urea derivatives as STING antagonists 库拉德夫制药私人有限公司 2024-05-10 CN claimed
WO-2023017452-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS CURADEV PHARMA PVT. LTD. (IN) 2023-02-16 WO claimed
US-20240360119-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS CURADEV PHARMA PVT. LTD. (IN) 2024-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360119-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS STING1, CGAS, SSB ROCK2 1718/4885MAPT 2509/4885POLB 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.